---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-049926"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:39:42.095603+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kintara Therapeutics gets Nasdaq delisting notice; equity at $731K vs $2.5M requirement

## Summary
- Received Nasdaq notice on Sept 20, 2023 for non-compliance with minimum stockholders' equity requirement of $2.5M; reported equity of $731,000 in FY 2023 10-K.
- Company has until Nov 6, 2023 to submit a plan to regain compliance; if accepted, may get up to 180-day extension.
- Also does not meet alternative listing standards: market value of listed securities ≥$35M or net income $500K from continuing operations.
- Common stock continues trading on Nasdaq under KTRA during compliance process; delisting could reduce liquidity and capital raising ability.

## SEC filing metadata
- accession: 0000950170-23-049926
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017023049926/0000950170-23-049926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017023049926/ktra-20230920.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-049926
- JSON: https://secwatch.observer/filing/0000950170-23-049926.json
- Plain text: https://secwatch.observer/filing/0000950170-23-049926.txt

## Key facts
- Listing & Compliance Notices
  TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: September 20, 2023, Kintara Therapeutics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, the Company reported stockholders’ equity of $73
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017023049926/0000950170-23-049926-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.